Pfizer today rolled out its TrumpRx initiative, offering more than 30 branded medicines at an average discount of 50% off list price and up to 85% for self-pay patients. Under Pfizer’s Most Favored Nation agreement with the U.S. government, this program immediately affects therapies for over 100 million Americans living with conditions such as migraines, rheumatoid arthritis, overactive bladder and atopic dermatitis. Insured and uninsured patients can access these discounts at nearly any U.S. pharmacy or via home delivery, supported through a partnership with GoodRx. The move is expected to reduce out-of-pocket expenses by hundreds of dollars per prescription for many primary-care treatments and select specialty brands.

In its fourth-quarter report, Pfizer delivered revenue 7% above consensus and non-GAAP EPS 12% ahead of forecasts, lifting its shares and contributing positively to the Dow Jones Industrial Average the following trading day. Revenue growth was driven by a 15% increase in oncology portfolio sales and a 20% rise in key hospital products, offsetting flat performance in its established medicines segment. Operating margin expanded by 180 basis points year-over-year, reflecting disciplined cost management and higher gross margins in recently launched vaccines. Management reiterated full-year guidance for mid-single-digit revenue growth and free cash flow above $20 billion.

Pfizer is positioning itself in the obesity market with a once-monthly GLP-1 candidate, MET-097i (Metsera), after VESPER-3 phase II topline data showed average weight reduction on par with leading injectable rivals. The 14-week trial enrolled 400 adults with BMI ≥30, reporting a mean weight loss of 12.8% from baseline and 65% of participants achieving ≥10% body-weight reduction. In 2026, Pfizer plans to initiate over 20 additional studies across multiple obesity and metabolic indications, aiming for a late-stage filing by 2028. Investors will watch trial enrollment rates, long-term safety data and potential label distinctions versus established therapies as key catalysts for market share gains.